New Potent Membrane-Targeting Antibacterial Peptides from Viral Capsid Proteins.
Identifieur interne : 000B90 ( PubMed/Curation ); précédent : 000B89; suivant : 000B91New Potent Membrane-Targeting Antibacterial Peptides from Viral Capsid Proteins.
Auteurs : Susana A. Dias [Portugal] ; João M. Freire [Portugal] ; Clara Pérez-Peinado [Espagne] ; Marco M. Domingues [Portugal] ; Diana Gaspar [Portugal] ; Nuno Vale [Portugal] ; Paula Gomes [Portugal] ; David Andreu [Espagne] ; S Nia T. Henriques [Australie] ; Miguel A R B. Castanho [Portugal] ; Ana S. Veiga [Portugal]Source :
- Frontiers in microbiology [ 1664-302X ] ; 2017.
Abstract
The increasing prevalence of multidrug-resistant bacteria urges the development of new antibacterial agents. With a broad spectrum activity, antimicrobial peptides have been considered potential antibacterial drug leads. Using bioinformatic tools we have previously shown that viral structural proteins are a rich source for new bioactive peptide sequences, namely antimicrobial and cell-penetrating peptides. Here, we test the efficacy and mechanism of action of the most promising peptides among those previously identified against both Gram-positive and Gram-negative bacteria. Two cell-penetrating peptides, vCPP 0769 and vCPP 2319, have high antibacterial activity against Staphylococcus aureus, MRSA, Escherichia coli, and Pseudomonas aeruginosa, being thus multifunctional. The antibacterial mechanism of action of the two most active viral protein-derived peptides, vAMP 059 and vCPP 2319, was studied in detail. Both peptides act on both Gram-positive S. aureus and Gram-negative P. aeruginosa, with bacterial cell death occurring within minutes. Also, these peptides cause bacterial membrane permeabilization and damage of the bacterial envelope of P. aeruginosa cells. Overall, the results show that structural viral proteins are an abundant source for membrane-active peptides sequences with strong antibacterial properties.
DOI: 10.3389/fmicb.2017.00775
PubMed: 28522994
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000B93
Links to Exploration step
pubmed:28522994Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">New Potent Membrane-Targeting Antibacterial Peptides from Viral Capsid Proteins.</title><author><name sortKey="Dias, Susana A" sort="Dias, Susana A" uniqKey="Dias S" first="Susana A" last="Dias">Susana A. Dias</name><affiliation wicri:level="1"><nlm:affiliation>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon, Portugal.</nlm:affiliation><country xml:lang="fr">Portugal</country><wicri:regionArea>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon</wicri:regionArea></affiliation></author><author><name sortKey="Freire, Joao M" sort="Freire, Joao M" uniqKey="Freire J" first="João M" last="Freire">João M. Freire</name><affiliation wicri:level="1"><nlm:affiliation>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon, Portugal.</nlm:affiliation><country xml:lang="fr">Portugal</country><wicri:regionArea>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon</wicri:regionArea></affiliation></author><author><name sortKey="Perez Peinado, Clara" sort="Perez Peinado, Clara" uniqKey="Perez Peinado C" first="Clara" last="Pérez-Peinado">Clara Pérez-Peinado</name><affiliation wicri:level="1"><nlm:affiliation>Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona Biomedical Research ParkBarcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona Biomedical Research ParkBarcelona</wicri:regionArea></affiliation></author><author><name sortKey="Domingues, Marco M" sort="Domingues, Marco M" uniqKey="Domingues M" first="Marco M" last="Domingues">Marco M. Domingues</name><affiliation wicri:level="1"><nlm:affiliation>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon, Portugal.</nlm:affiliation><country xml:lang="fr">Portugal</country><wicri:regionArea>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon</wicri:regionArea></affiliation></author><author><name sortKey="Gaspar, Diana" sort="Gaspar, Diana" uniqKey="Gaspar D" first="Diana" last="Gaspar">Diana Gaspar</name><affiliation wicri:level="1"><nlm:affiliation>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon, Portugal.</nlm:affiliation><country xml:lang="fr">Portugal</country><wicri:regionArea>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon</wicri:regionArea></affiliation></author><author><name sortKey="Vale, Nuno" sort="Vale, Nuno" uniqKey="Vale N" first="Nuno" last="Vale">Nuno Vale</name><affiliation wicri:level="1"><nlm:affiliation>UCIBIO-REQUIMTE, Faculdade de Farmácia, Universidade do PortoPorto, Portugal.</nlm:affiliation><country xml:lang="fr">Portugal</country><wicri:regionArea>UCIBIO-REQUIMTE, Faculdade de Farmácia, Universidade do PortoPorto</wicri:regionArea></affiliation></author><author><name sortKey="Gomes, Paula" sort="Gomes, Paula" uniqKey="Gomes P" first="Paula" last="Gomes">Paula Gomes</name><affiliation wicri:level="1"><nlm:affiliation>LAQV-REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do PortoPorto, Portugal.</nlm:affiliation><country xml:lang="fr">Portugal</country><wicri:regionArea>LAQV-REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do PortoPorto</wicri:regionArea></affiliation></author><author><name sortKey="Andreu, David" sort="Andreu, David" uniqKey="Andreu D" first="David" last="Andreu">David Andreu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona Biomedical Research ParkBarcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona Biomedical Research ParkBarcelona</wicri:regionArea></affiliation></author><author><name sortKey="Henriques, S Nia T" sort="Henriques, S Nia T" uniqKey="Henriques S" first="S Nia T" last="Henriques">S Nia T. Henriques</name><affiliation wicri:level="1"><nlm:affiliation>Institute for Molecular Bioscience, The University of Queensland, BrisbaneQLD, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Institute for Molecular Bioscience, The University of Queensland, BrisbaneQLD</wicri:regionArea></affiliation></author><author><name sortKey="Castanho, Miguel A R B" sort="Castanho, Miguel A R B" uniqKey="Castanho M" first="Miguel A R B" last="Castanho">Miguel A R B. Castanho</name><affiliation wicri:level="1"><nlm:affiliation>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon, Portugal.</nlm:affiliation><country xml:lang="fr">Portugal</country><wicri:regionArea>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon</wicri:regionArea></affiliation></author><author><name sortKey="Veiga, Ana S" sort="Veiga, Ana S" uniqKey="Veiga A" first="Ana S" last="Veiga">Ana S. Veiga</name><affiliation wicri:level="1"><nlm:affiliation>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon, Portugal.</nlm:affiliation><country xml:lang="fr">Portugal</country><wicri:regionArea>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28522994</idno><idno type="pmid">28522994</idno><idno type="doi">10.3389/fmicb.2017.00775</idno><idno type="wicri:Area/PubMed/Corpus">000B93</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B93</idno><idno type="wicri:Area/PubMed/Curation">000B90</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B90</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">New Potent Membrane-Targeting Antibacterial Peptides from Viral Capsid Proteins.</title><author><name sortKey="Dias, Susana A" sort="Dias, Susana A" uniqKey="Dias S" first="Susana A" last="Dias">Susana A. Dias</name><affiliation wicri:level="1"><nlm:affiliation>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon, Portugal.</nlm:affiliation><country xml:lang="fr">Portugal</country><wicri:regionArea>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon</wicri:regionArea></affiliation></author><author><name sortKey="Freire, Joao M" sort="Freire, Joao M" uniqKey="Freire J" first="João M" last="Freire">João M. Freire</name><affiliation wicri:level="1"><nlm:affiliation>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon, Portugal.</nlm:affiliation><country xml:lang="fr">Portugal</country><wicri:regionArea>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon</wicri:regionArea></affiliation></author><author><name sortKey="Perez Peinado, Clara" sort="Perez Peinado, Clara" uniqKey="Perez Peinado C" first="Clara" last="Pérez-Peinado">Clara Pérez-Peinado</name><affiliation wicri:level="1"><nlm:affiliation>Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona Biomedical Research ParkBarcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona Biomedical Research ParkBarcelona</wicri:regionArea></affiliation></author><author><name sortKey="Domingues, Marco M" sort="Domingues, Marco M" uniqKey="Domingues M" first="Marco M" last="Domingues">Marco M. Domingues</name><affiliation wicri:level="1"><nlm:affiliation>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon, Portugal.</nlm:affiliation><country xml:lang="fr">Portugal</country><wicri:regionArea>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon</wicri:regionArea></affiliation></author><author><name sortKey="Gaspar, Diana" sort="Gaspar, Diana" uniqKey="Gaspar D" first="Diana" last="Gaspar">Diana Gaspar</name><affiliation wicri:level="1"><nlm:affiliation>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon, Portugal.</nlm:affiliation><country xml:lang="fr">Portugal</country><wicri:regionArea>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon</wicri:regionArea></affiliation></author><author><name sortKey="Vale, Nuno" sort="Vale, Nuno" uniqKey="Vale N" first="Nuno" last="Vale">Nuno Vale</name><affiliation wicri:level="1"><nlm:affiliation>UCIBIO-REQUIMTE, Faculdade de Farmácia, Universidade do PortoPorto, Portugal.</nlm:affiliation><country xml:lang="fr">Portugal</country><wicri:regionArea>UCIBIO-REQUIMTE, Faculdade de Farmácia, Universidade do PortoPorto</wicri:regionArea></affiliation></author><author><name sortKey="Gomes, Paula" sort="Gomes, Paula" uniqKey="Gomes P" first="Paula" last="Gomes">Paula Gomes</name><affiliation wicri:level="1"><nlm:affiliation>LAQV-REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do PortoPorto, Portugal.</nlm:affiliation><country xml:lang="fr">Portugal</country><wicri:regionArea>LAQV-REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do PortoPorto</wicri:regionArea></affiliation></author><author><name sortKey="Andreu, David" sort="Andreu, David" uniqKey="Andreu D" first="David" last="Andreu">David Andreu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona Biomedical Research ParkBarcelona, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona Biomedical Research ParkBarcelona</wicri:regionArea></affiliation></author><author><name sortKey="Henriques, S Nia T" sort="Henriques, S Nia T" uniqKey="Henriques S" first="S Nia T" last="Henriques">S Nia T. Henriques</name><affiliation wicri:level="1"><nlm:affiliation>Institute for Molecular Bioscience, The University of Queensland, BrisbaneQLD, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Institute for Molecular Bioscience, The University of Queensland, BrisbaneQLD</wicri:regionArea></affiliation></author><author><name sortKey="Castanho, Miguel A R B" sort="Castanho, Miguel A R B" uniqKey="Castanho M" first="Miguel A R B" last="Castanho">Miguel A R B. Castanho</name><affiliation wicri:level="1"><nlm:affiliation>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon, Portugal.</nlm:affiliation><country xml:lang="fr">Portugal</country><wicri:regionArea>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon</wicri:regionArea></affiliation></author><author><name sortKey="Veiga, Ana S" sort="Veiga, Ana S" uniqKey="Veiga A" first="Ana S" last="Veiga">Ana S. Veiga</name><affiliation wicri:level="1"><nlm:affiliation>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon, Portugal.</nlm:affiliation><country xml:lang="fr">Portugal</country><wicri:regionArea>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon</wicri:regionArea></affiliation></author></analytic><series><title level="j">Frontiers in microbiology</title><idno type="ISSN">1664-302X</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The increasing prevalence of multidrug-resistant bacteria urges the development of new antibacterial agents. With a broad spectrum activity, antimicrobial peptides have been considered potential antibacterial drug leads. Using bioinformatic tools we have previously shown that viral structural proteins are a rich source for new bioactive peptide sequences, namely antimicrobial and cell-penetrating peptides. Here, we test the efficacy and mechanism of action of the most promising peptides among those previously identified against both Gram-positive and Gram-negative bacteria. Two cell-penetrating peptides, vCPP 0769 and vCPP 2319, have high antibacterial activity against Staphylococcus aureus, MRSA, Escherichia coli, and Pseudomonas aeruginosa, being thus multifunctional. The antibacterial mechanism of action of the two most active viral protein-derived peptides, vAMP 059 and vCPP 2319, was studied in detail. Both peptides act on both Gram-positive S. aureus and Gram-negative P. aeruginosa, with bacterial cell death occurring within minutes. Also, these peptides cause bacterial membrane permeabilization and damage of the bacterial envelope of P. aeruginosa cells. Overall, the results show that structural viral proteins are an abundant source for membrane-active peptides sequences with strong antibacterial properties.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">28522994</PMID><DateCreated><Year>2017</Year><Month>05</Month><Day>19</Day></DateCreated><DateRevised><Year>2017</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-302X</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><PubDate><Year>2017</Year></PubDate></JournalIssue><Title>Frontiers in microbiology</Title><ISOAbbreviation>Front Microbiol</ISOAbbreviation></Journal><ArticleTitle>New Potent Membrane-Targeting Antibacterial Peptides from Viral Capsid Proteins.</ArticleTitle><Pagination><MedlinePgn>775</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmicb.2017.00775</ELocationID><Abstract><AbstractText>The increasing prevalence of multidrug-resistant bacteria urges the development of new antibacterial agents. With a broad spectrum activity, antimicrobial peptides have been considered potential antibacterial drug leads. Using bioinformatic tools we have previously shown that viral structural proteins are a rich source for new bioactive peptide sequences, namely antimicrobial and cell-penetrating peptides. Here, we test the efficacy and mechanism of action of the most promising peptides among those previously identified against both Gram-positive and Gram-negative bacteria. Two cell-penetrating peptides, vCPP 0769 and vCPP 2319, have high antibacterial activity against Staphylococcus aureus, MRSA, Escherichia coli, and Pseudomonas aeruginosa, being thus multifunctional. The antibacterial mechanism of action of the two most active viral protein-derived peptides, vAMP 059 and vCPP 2319, was studied in detail. Both peptides act on both Gram-positive S. aureus and Gram-negative P. aeruginosa, with bacterial cell death occurring within minutes. Also, these peptides cause bacterial membrane permeabilization and damage of the bacterial envelope of P. aeruginosa cells. Overall, the results show that structural viral proteins are an abundant source for membrane-active peptides sequences with strong antibacterial properties.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dias</LastName><ForeName>Susana A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freire</LastName><ForeName>João M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Virology, Institut PasteurParis, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pérez-Peinado</LastName><ForeName>Clara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona Biomedical Research ParkBarcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domingues</LastName><ForeName>Marco M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaspar</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vale</LastName><ForeName>Nuno</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>UCIBIO-REQUIMTE, Faculdade de Farmácia, Universidade do PortoPorto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomes</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>LAQV-REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do PortoPorto, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andreu</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona Biomedical Research ParkBarcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henriques</LastName><ForeName>Sónia T</ForeName><Initials>ST</Initials><AffiliationInfo><Affiliation>Institute for Molecular Bioscience, The University of Queensland, BrisbaneQLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castanho</LastName><ForeName>Miguel A R B</ForeName><Initials>MARB</Initials><AffiliationInfo><Affiliation>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veiga</LastName><ForeName>Ana S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de LisboaLisbon, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Microbiol</MedlineTA><NlmUniqueID>101548977</NlmUniqueID><ISSNLinking>1664-302X</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Int J Med Microbiol. 2010 Feb;300(2-3):148-54</RefSource><PMID Version="1">19896895</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Biophys J. 2011 Apr;40(4):387-97</RefSource><PMID Version="1">21336522</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Drug Discov. 2015 Dec;14(12):821-32</RefSource><PMID Version="1">26493767</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Bacteriol. 1999 Aug;181(16):4725-33</RefSource><PMID Version="1">10438737</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2015 Aug 7;290(32):19853-62</RefSource><PMID Version="1">26100634</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antimicrob Agents Chemother. 2011 Jul;55(7):3446-52</RefSource><PMID Version="1">21518845</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochim Biophys Acta. 2015 May;1848(5):1139-46</RefSource><PMID Version="1">25680229</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Carbohydr Polym. 2017 Jun 1;165:384-393</RefSource><PMID Version="1">28363563</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Future Microbiol. 2015;10(7):1103-6</RefSource><PMID Version="1">26118303</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochemistry. 2003 Dec 9;42(48):14130-8</RefSource><PMID Version="1">14640680</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8245-50</RefSource><PMID Version="1">10890923</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bioinformatics. 2015 Jul 15;31(14):2252-6</RefSource><PMID Version="1">25725499</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Pathog. 2010 Oct 28;6(10):e1001067</RefSource><PMID Version="1">21060861</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Pathog. 2013;9(6):e1003425</RefSource><PMID Version="1">23785287</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FASEB J. 2004 Feb;18(2):394-6</RefSource><PMID Version="1">14656995</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bioinformatics. 2012 Jan 1;28(1):130-1</RefSource><PMID Version="1">22053077</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Interdiscip Perspect Infect Dis. 2014;2014:541340</RefSource><PMID Version="1">25140175</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Front Cell Infect Microbiol. 2016 Dec 27;6:194</RefSource><PMID Version="1">28083516</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biophys. 2011;2011:414729</RefSource><PMID Version="1">21687343</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2005 Sep 15;192(6):1023-8</RefSource><PMID Version="1">16107955</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell Mol Life Sci. 2009 Dec;66(23):3821-6</RefSource><PMID Version="1">19701717</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Protoc. 2008;3(2):163-75</RefSource><PMID Version="1">18274517</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2002 Jan 24;415(6870):389-95</RefSource><PMID Version="1">11807545</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Microbiol. 2009 Mar;7(3):245-50</RefSource><PMID Version="1">19219054</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Transl Med. 2013 Mar 22;11:74</RefSource><PMID Version="1">23517638</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Microbiol Rev. 2006 Jul;19(3):491-511</RefSource><PMID Version="1">16847082</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 1999 Mar;179 Suppl 2:S326-30</RefSource><PMID Version="1">10081503</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Immunol Rev. 2004 Apr;198:169-84</RefSource><PMID Version="1">15199962</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>P T. 2015 Apr;40(4):277-83</RefSource><PMID Version="1">25859123</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmaceuticals (Basel). 2013 Nov 28;6(12):1543-75</RefSource><PMID Version="1">24287494</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochim Biophys Acta. 2013 Feb;1828(2):223-32</RefSource><PMID Version="1">23085001</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2003 Jan 10;278(2):1310-5</RefSource><PMID Version="1">12417587</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FEBS J. 2015 Jun;282(12):2267-78</RefSource><PMID Version="1">25808179</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Prog Lipid Res. 2012 Apr;51(2):149-77</RefSource><PMID Version="1">22245454</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochim Biophys Acta. 2007 May;1768(5):1277-90</RefSource><PMID Version="1">17383609</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Mol Microbiol Biotechnol. 2011;20(4):228-35</RefSource><PMID Version="1">21894027</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Biotechnol. 2011 Sep;29(9):464-72</RefSource><PMID Version="1">21680034</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Peptides. 2003 Nov;24(11):1681-91</RefSource><PMID Version="1">15019199</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochem Biophys Res Commun. 2006 Oct 20;349(2):769-74</RefSource><PMID Version="1">16945333</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biochem J. 2006 Oct 1;399(1):1-7</RefSource><PMID Version="1">16956326</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antimicrob Agents Chemother. 1999 May;43(5):1274-6</RefSource><PMID Version="1">10223951</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2009 Dec 22;4(12):e8385</RefSource><PMID Version="1">20027298</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Chembiochem. 2013 Oct 11;14(15):2013-22</RefSource><PMID Version="1">24038773</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Pept Sci. 2011 May;17(5):335-41</RefSource><PMID Version="1">21294230</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Antimicrob Agents. 2011 Sep;38(3):217-25</RefSource><PMID Version="1">21733662</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Infect Dis. 2001 Oct;1(3):156-64</RefSource><PMID Version="1">11871492</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Appl Environ Microbiol. 1997 Jun;63(6):2421-31</RefSource><PMID Version="1">9172364</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacol Rev. 2003 Mar;55(1):27-55</RefSource><PMID Version="1">12615953</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biopolymers. 2002;66(4):236-48</RefSource><PMID Version="1">12491537</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Antimicrob Chemother. 2013 Mar;68(3):674-7</RefSource><PMID Version="1">23179561</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antimicrob Agents Chemother. 1994 Oct;38(10):2311-6</RefSource><PMID Version="1">7840562</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Bacteriol. 2000 Feb;182(4):1172-5</RefSource><PMID Version="1">10648548</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Infect Dis Clin North Am. 2009 Dec;23(4):791-815, vii</RefSource><PMID Version="1">19909885</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Microbiol. 2005 Mar;3(3):238-50</RefSource><PMID Version="1">15703760</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2010 Sep 3;285(36):27536-44</RefSource><PMID Version="1">20566635</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antimicrobial peptides (AMPs)</Keyword><Keyword MajorTopicYN="N">atomic force microscopy (AFM)</Keyword><Keyword MajorTopicYN="N">cell-penetrating peptides (CPPs)</Keyword><Keyword MajorTopicYN="N">membrane permeabilization</Keyword><Keyword MajorTopicYN="N">minimal bactericidal concentration (MBC)</Keyword><Keyword MajorTopicYN="N">minimum inhibitory concentration (MIC)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>02</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>04</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28522994</ArticleId><ArticleId IdType="doi">10.3389/fmicb.2017.00775</ArticleId><ArticleId IdType="pmc">PMC5415599</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B90 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000B90 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:28522994
|texte= New Potent Membrane-Targeting Antibacterial Peptides from Viral Capsid Proteins.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:28522994" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |